



2FW 1647 \$

PATENT  
ATTORNEY DOCKET No. 54458-20002.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Anton WELLSTEIN ) Group Art Unit: 1647  
Application Number: 09/880,097 ) Examiner: Nichols, Christopher J  
Filed: June 14, 2001 )  
Title: PLEIOTROPHIN GROWTH FACTOR RECEPTOR FOR THE TREATMENT OF  
PROLIFERATIVE, VASCULAR AND NEUROLOGICAL DISORDERS

Commissioner of Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicant is submitting herewith copies of the references listed on the attached Form PTO-1449 for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Consideration of the foregoing plus the prompt return of a copy of the enclosed PTO Form-1449 with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested. In addition, enclosed is a copy of the International Search Report dated November 28, 2002.

This Information Disclosure Statement is being submitted after receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance. A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this

07/21/2004 CCHAU1 00000154 031952 09880097

01 FC:1806 180.00 DA


submission in duplicate. However, in the event any additional fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 03-1952.

Respectfully submitted,

MORRISON & FOERSTER LLP

Dated: July 20, 2004

By:



James Remenick  
Registration No. 36,902

**Customer Number 25227**  
Morrison & Foerster LLP  
1650 Tyson's Boulevard  
Suite 300  
McLean, Virginia 22102  
(703) 760-7700 (telephone)  
(703) 760-7777 (facsimile)

Form PTO-1449

Docket Number: 544582000200

Application Number (serialno)

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Anton WELLSTEIN

Filing Date: June 14, 2001

Group Art Unit: 1647

Mailing Date: July 14, 2004

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	06/23/1998	5,770,421	Morris et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	2.	04/13/2000	00/20869	WIPO			x
	3.						

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	4.	Kung Meng et al., (Pleiotrophin signals increased tyrosine phosphorylation of b-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase B/γ) March 14, 2000, Vol. 97 no 6 pp. 2603-2608
	5.	Nobuaki Maeda et al., (A Receptor-like Protein-tyrosine Phosphatase PTP/RPTPB Binds a Heparin-binding Growth Factor Midkine) Vol. 274, No. 18. Issue of April 33, pp. 12474-12479.
	6.	Nobuaki Maeda et al., (6B4 Proteoglycan/Phosphacan, an Extracellular Variant of Receptor-like Protein-tyrosine Phosphatase RPTPB, Binds Pleiotrophin/Heparin-binding Growth-associated Molecule (HB-GAM)* Vol. 271, No. 35, Issue of August 30, pp. 21446-21452
	7.	Erkki Raulo et al., (Isolation of a Neuronal Cell Surface Receptor of Heparin Binding Growth-associated Molecule (HB-GAM) Vol. 269, No. 17, Issue of April 29, pp. 12999-13004
	8.	K. Matsumoto et al., (A novel family of heparin-binding growth factors, pleiotrophin and midkine, is expressed in the developing rat cerebral cortex) Developmental Brain Research 79 (1994) 229-241
	9.	Nan Zhang et al., (Domain Structure of Pleiotrophin Required for Transformation) Vol. 274, No. 19, Issue of May 7, pp. 12959-12962
	10.	Dorothy J. Caughey et al., (Fractionation of polyclonal antibodies to fragments of a neuroreceptor using three increasingly chaotropic solvents) Journal of Chromatography B, 728 (1999) 49-57
	11.	Stephan W. Morris et al., (ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neutral receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene (1997) 14, 2175-2188

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number: 544582000200

Application Number (serialno)

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)


Applicant

Anton WELLSTEIN

Filing Date: June 14, 2001

Group Art Unit: 1647

Mailing Date: July 14, 2004

- 
- |     |   |
|-----|---|
| 12. | Toshinori Iwahara et al., (Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system) Oncogene (1997) 14, 439-449  |
| 13. | Karen Pulford et al., (Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM) – ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1) Blood, Vol. No. 4, February 15, 1997: pp. 1394-1404   |
| 14. | A. Aigner, et al., (Identification of a Receptor for the Growth Factor Pleiotrophin, its Signal Transduction and Potential Role in Cancer) Proceedings of AACR; Vol. 40, p. 732; March 1999.  |
| 15. | Gerald E. Stoica et al., (Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin) Vol. 276, No. 20, Issue of May 18, pp. 16772-16779   |
| 16. | James A. Wells, (Additivity of Mutational Effects of Proteins), Biochemistry Vol. 29, No. 37, September 18, 1990  |
| 17. | Nobuaki Maeda et al., (A Receptor-like Protein-tyrosine Phosphatase PTP/RPTP B Binds a Herparin-binding Growth Factor Midkine) Vol. 274, No. 18, Issue of April 30, pp. 12474-12479   |
| 18. | Temple F. Smith et al., (The challenges of genome sequence annotation or "The devil is in the details") Nature Biotechnology Volume 15, November 1997   |
| 19. | Jeffrey Skolnick et al., (From genes to protein structure and function: novel applications of computational approaches in the genomic era) Tibtech January 2000, Vol. 18, pp 34-39.   |
| 20. | Genetwork (Go hunting in sequence database but watch out for the traps) TIG October 1996, Vol. 12, No. 10, pp. 425-427  |
| 21. | Peer Bork (Powers and Pitfalls in Sequence Analysis: The 70% Hurdle) Cold Spring Harbor Laboratory Press (2000) pp. 398-400   |
| 22. | Kung Meng., (Pleiotrophin signals increased tyrosine phosphorylation of B-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase B/ζ) PNAS, March 14, 2000, Vol. 97, No. 6, pp. 2603-2608 |
| 23. | Gerald E. Stoica., (Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin*), Journal of Biological Chemistry, Vol. 276, No. 20, Issue of May 18, pp. 16772-16779  |
| 24. | Kenneith M. Merz, Jr. et al., (The Protein Folding Problem and Tertiary Structure Prediction) Birkhäuser Boston 1994, Ch 14, pp. 433-506.   |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.